Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Steroidogenic 17beta-HSD2 inhibition for targeted intracrine therapy in bone fracture healing

March 12, 2019

Extended evaluation phase findings from SONICS study of Recorlev in endogenous Cushing's syndrome

March 12, 2019

FDA clears Rubius' IND application for phase Ib trial of RTX-134 for PKU

March 11, 2019

Saniona initiates phase IIa study of Tesomet for hypothalamic obesity

March 11, 2019

Saint Louis University discloses ESRRG inverse agonists

March 11, 2019

PROLONG study of Makena does not meet coprimary endpoints

March 11, 2019

Agios Pharmaceuticals patents PKLR activators

March 8, 2019

Novo Nordisk initiates phase II study of NNC-0174-0833 for weight management

March 8, 2019

Completion of phase Ia study of FOR-6219 for endometriosis paves way for phase Ib

March 7, 2019

Bifunctional TFR1 ligand-peptides as erythroblast-targeted gene therapy for erythroid disorders

March 7, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...